Comparison of the Safety and Tolerance of Intravenous Anisoylated Plasminogen Streptokinase Activator Complex and Intracoronary Streptokinase in Acute Myocardial Infarction J. B. R. M. de Swart Short Communication 18 October 2012 Pages: 279 - 281
Safety and Side Effects of Anisoylated Plasminogen Streptokinase Activator Complex and Streptokinase in Patients with Acute Myocardial Infarction J. -P. MonassierM. Haussen Section 5: Safety and Tolerance Data 18 October 2012 Pages: 282 - 285
Treatment of Acute Myocardial Infarction with Anisoylated Plasminogen Streptokinase Activator Complex in a District Hospital D. A. Chamberlain Short Communication 18 October 2012 Pages: 286 - 286
Safety and Tolerance Data from the Belgian Multicentre Study of Anisoylated Plasminogen Streptokinase Activator Complex versus Heparin in Acute Myocardial Infarction Leo L. Bossaert Section 5: Safety and Tolerance Data 18 October 2012 Pages: 287 - 292
Preliminary Safety and Tolerance Data Obtained in the Comparative Study of Anisoylated Plasminogen Streptokinase Activator Complex versus Heparin E. A. P. Croydon Section 5: Safety and Tolerance Data 18 October 2012 Pages: 293 - 296
Discussion J. J. R. M. BonnierD. A. Chamberlain Section 5: Safety and Tolerance Data 18 October 2012 Pages: 297 - 297
An Interim Report of the Efficacy and Safety of Anisoylated Plasminogen Streptokinase Activator Complex (APSAC) E. Stewart JohnsonR. J. Cregeen Section 6: Anisoylated Plasminogen Streptokinase Activator Complex in Perspective 18 October 2012 Pages: 298 - 311
Panel Discussion K. R. L. MansfordJ. AndersonS. Sherry Section 6: Anisoylated Plasminogen Streptokinase Activator Complex in Perspective 18 October 2012 Pages: 312 - 316
